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Aims EPHESUS was a multicentre, double-blind clinical trial in which 6632 patients with acute myocardial infarction (AMI)
complicated by LV systolic dysfunction (LVSD) were randomized to receive eplerenone (n = 3319) or placebo (n =
3313). A total of 1580 EPHESUS patients were treated with PCI, which is now the standard treatment for AMI. This
EPHESUS substudy examined the effects of eplerenone upon cardiovascular outcomes in PCI-treated patients.
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Methods
and results
EPHESUS patients were divided into PCI-treated and non-PCI-treated cohorts, and the effect of eplerenone upon
mortality and other major adverse cardiovascular outcomes was assessed in each cohort. The PCI-treated patients
(n = 1580) were younger, and had better renal function and fewer co-morbidities than non-PCI-treated patients (n
= 5052). Cardiovascular mortality was significantly lower in PCI-treated patients as compared with non-PCI-treated
patients (7% vs. 16%, P < 0.0001). However, the incidence of non-fatal events was similar in PCI-treated and non-
PCI-treated cohorts. There was no statistical difference between the PCI-treated and non-PCI-treated cohorts in the
primary or secondary outcomes of the trial. Eplerenone administration, compared with placebo, in the PCI-treated
cohort did not affect PCI-related clinical outcomes, including recurrence of angina, the occurrence of acute coronary
syndromes, or the need for further revascularization.
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Conclusions The beneficial effects of eplerenone in the EPHESUS trial exist for both PCI- and non-PCI-treated AMI patients with
LVSD. Eplerenone has minimal, if any, effect upon reducing PCI-related adverse events in the PCI-treated cohort.
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Introduction
Acute myocardial infarction (AMI) and consequent LV systolic dys-
function (LVSD) are the leading causes of morbidity and mortality.
Mineralocorticoid receptor (MR) antagonism with eplerenone has
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. been shown to improve survival and reduce hospitalization due
to cardiovascular events in patients with AMI and LVSD in the
landmark EPHESUS (Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival Study) trial.1 In this trial, a mean
dose of 43mg of eplerenone produced a significant reduction in
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all-cause and cardiovascular mortality compared with placebo.1
National and international guidelines therefore strongly recom-
mend using MR antagonists for patients with post-infarct LVSD.2,3
In contemporary practice, patients with AMI are usually treated
with PCI, involving balloon angioplasty and stent implantation.4,5
However, only a quarter of patients in the EPHESUS trial received
PCI for treatment of AMI while others were treated with throm-
bolysis, coronary artery bypass grafting (CABG), or conservative
medical treatment.1 Therefore, application of the EPHESUS data
to current practice can be questioned. We aimed to evaluate the
impact of eplerenone administration in heart failure among patients
managed with PCI.
Experimental data have suggested that eplerenone may improve
the PCI outcomes by reducing neointimal proliferation6 and
accelerating endothelial regeneration.7,8 While pre-clinical studies
support these hypotheses,9–11 there has been no study investigat-
ing this potential benefit of eplerenone in humans. Although the
EPHESUS trial did not have a pre-specified aim to examine PCI
outcomes, and there was no routine angiographic follow-up, sur-
rogate clinical markers were systematically recorded. The second
objective of this study was to evaluate the impact of eplerenone
upon PCI-related adverse clinical outcomes, including recurrence
of angina, the occurrence of acute coronary syndromes, and the
need for repeat revascularization.
Methods
EPHESUS trial
EPHESUS was a large multicentre, double-blind randomized controlled
clinical trial that assessed the impact of eplerenone upon clinical
outcomes in patients with LVSD after AMI.1 Patients (n= 6632) were
randomized to receive eplerenone (n= 3319) or placebo (n= 3313).
Eplerenone was initiated at 25mg/day at ∼7 days after AMI and titrated
at 4 weeks to 50mg/day, if serum potassium was <5mmol/L. About
24% patients in the EPHESUS trial received PCI as a treatment of AMI
while others were treated with thrombolysis (27%), CABG (1%), or
conservative medical treatment (48%). Patients were followed-up for
an average of 16 months.
EPHESUS PCI substudy
This substudy evaluated the effect of eplerenone administration in the
PCI-treated subgroup of patients in the EPHESUS trial. We analysed
the PCI-treated (n=1580) vs. non-PCI-treated (n= 5052) patients.
Furthermore, we compared the baseline characteristics and clinical
outcomes in PCI-treated patients in the eplerenone- (n= 799) and
placebo- (n= 781) treated groups.
Statistical analysis
Data are presented as mean± SD or proportion and percent-
age, as indicated. Continuous variables were analysed using the
Mann–Whitney test and categorical variables with the 𝜒2 test. Mul-
tivariate analyses were performed using the Cox regression method.
Hazard ratios (HRs) along with the 95% confidence interval (CI) are
presented. P-values <0.05 were considered significant. All statistical
analyses were performed using SAS® 9.2 software (SAS Institute,
Cary, NC, USA). ..
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The EPHESUS PCI cohort is different
from the non-PCI cohort
The baseline demographic and clinical characteristics of PCI-
treated (n=1580) and non-PCI-treated (n= 5052) patients in the
EPHESUS trial are shown in Table 1. The PCI-treated patients were
younger, and had better renal function, fewer co-morbidities, and
higher prescription of evidence-based medication including beta-
blockers, ACE inhibitors, and statins. Cardiovascular mortality was
significantly lower in PCI-treated patients as compared with non-
PCI-treated patients (7% vs. 16%, P< 0.0001), but the incidence of
non-fatal events was similar in the two groups (Table 1).
Eplerenone improves outcomes in both
the PCI-treated and the non-PCI-treated
cohort
Eplerenone treatment was similarly effective in reducing mortal-
ity, cardiovascular events, and hospitalization in both PCI-treated
and non-PCI-treated AMI patients with LVSD (Figure 1). On mul-
tivariate Cox regression analysis, with eplerenone and PCI as
co-variables, both PCI and eplerenone administration were inde-
pendently associated with better clinical outcomes (Table 2).
Baseline characteristics of the EPHESUS
PCI cohort
The baseline characteristics of the EPHESUS PCI cohort treated
with placebo or eplerenone were similar (Table 3). The mean age
of the patients was 60 years, with 77% male patients. The two
groups were similar in terms of age, gender, ethnicity, LV func-
tion, co-morbidities, and prescription of medication at discharge
(Table 3). There was no significant difference in adverse events
between the eplerenone- or placebo-treated EPHESUS PCI cohort:
hyperkalaemia (2.4% vs. 3.3%, P= 0.33), hypokalaemia (1.7% vs.
0.8%, P= 0.10), gynaecomastia in men (0.6% vs. 0.6%, P=1.00),
and renal dysfunction (3.2% vs. 2.0%, P= 0.13).
Eplerenone does not affect PCI-related
clinical outcomes
Eplerenone, compared with placebo, in the PCI cohort did not
impact upon the incidence of sudden cardiac death, non-fatal MI,
or stroke (Table 4). Although there was a statistically significant
reduction in events related to heart failure and hospital admissions,
there was no effect upon PCI-related adverse outcomes, including
recurrence of angina pectoris, unstable angina, AMI, or need for
further revascularization (Table 4).
Discussion
This substudy analysis of the EPHESUS trial has highlighted that
eplerenone is effective in patients with AMI and LVSD whether
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Table 1 Baseline comparison of PCI-treated and non-PCI-treated EPHESUS patients
Characteristic Non-PCI treated,
n= 5052 (76%)
PCI treated,
n= 1580 (24%)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n Mean±SD
or n (%)
n Mean±SD
or n (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 5052 65± 11 1580 61±12 <0.0001
Caucasian 4589 (91%) 1395 (88%) 0.003
Male 3491 (69%) 1223 (77%) <0.0001
Time from AMI to randomization (days) 5051 7.4± 2.9 1580 6.7± 3.0 <0.0001
Clinical
Blood pressure (mmHg)
Systolic 5050 120±17 1580 116± 16 <0.0001
Diastolic 5050 73± 11 1580 70± 11 <0.0001
LV ejection fraction (%) 5041 33± 6 1576 33± 6 0.85
Previous hospitalization for HF 452 (9%) 60 (4%) <0.0001
Symptoms of heart failure 4347 (87%) 1232 (79%) <0.0001
Potassium (mmol/L) 5029 4.28± 0.45 1566 4.21± 0.43 <0.0001
Creatinine (μmol/L) 5026 102± 29 1558 95± 25 <0.0001
eGFR (MDRD, mL/min/1.73m2) 4888 67± 19 1493 74± 19 <0.0001
Medical history 5052 1580
Previous MI 1467 (29%) 336 (21%) <0.0001
Diabetes mellitus 1658 (33%) 484 (31%) 0.10
Heart failure 853 (17%) 122 (8%) <0.0001
Hypertension 3159 (63%) 848 (54%) <0.0001
Medications 5052 1580
ACEI/ARB 4318 (85%) 1433 (91%) < 0.0001
Beta-blockers 3641 (72%) 1320 (84%) < 0.0001
Diuretics 3172 (63%) 812 (51%) < 0.0001
Aspirin 4377 (87%) 1493 (94%) < 0.0001
Anticoagulants 934 (18%) 174 (11%) < 0.0001
Statins 2026 (40%) 1069 (68%) < 0.0001
Outcomes 5052 1580
Cardiovascular mortality 784 (16%) 106 (7%) <0.0001
Non-fatal events (ACS/revascularization) 1073 (21%) 339 (21%) 0.85
ACEI, ACE inhibitor, ACS, acute coronary syndrome; AMI, acute myocardial infarction; eGFR, estimated glomerular filtration rate [four-variable Modification of Diabetes in
Renal Disease (MDRD) formula]; HF, heart failure; PCI, percutaneous coronary intervention.
treated with or without PCI. However, there is no evidence that
eplerenone has any impact upon PCI-related outcomes including
recurrence of angina, AMI, and repeat revascularization.
Eplerenone improved outcomes in both
the PCI-treated and non-PCI-treated
population
Mineralocorticoid receptor antagonists are strongly recommended
for patients with LVSD and symptoms of heart failure,12,13 based
on morbidity and mortality benefits seen in three landmark tri-
als: RALES, EPHESUS, and EMPHASIS-HF.1,14,15 The RALES trial
consisted of patients with advanced heart failure, the EPHESUS
trial included patients with LVSD after AMI, and the EMPHASIS-
HF trial enrolled patients with heart failure and mild (NYHA class .
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.. II) symptoms.1,14–16 In RALES, spironolactone produced 30% rel-
ative reduction in mortality during an average follow-up of 24
months.14 In EMPHASIS-HF, eplerenone was associated with a
24% reduction in cardiovascular death and a 42% reduction in
hospitalization for heart failure.15 Only the EPHESUS trial specifi-
cally examined patients with LVSD after an AMI and showed that
eplerenone produced 15% reduction in all-cause mortality, 17%
reduction in cardiovascular mortality, and 21% reduction in sud-
den cardiac death.1 In contemporary practice, most patients with
AMI receive PCI treatment.4 Our data show that eplerenone con-
fers similar benefit in patients with AMI and LVSD whether or
not they are treated with PCI. The outcomes observed in the
PCI subgroup were similar to those reported in the full EPHESUS
cohort.1 Our analysis shows that PCI itself was associated with a
major reduction in adverse outcomes in AMI patients, consistent
© 2014 The Authors
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Figure 1 Outcomes in PCI-treated and non-PCI-treated EPHESUS patients. Outcomes for both cohorts are shown as the hazard ratio (HR)
with the 95% confidence interval (CI). The 95% CI for all HR values between PCI-treated and non-PCI-treated EPHESUS patients overlap with
each other (shown in grey shade). CV, cardiovascular; PCI, percutaneous coronary intervention.
Table 2 Association of outcomes with eplerenone and PCI in EPHESUS patients in multivariable Cox regression
analysis with eplerenone and PCI as covariables
Eplerenone, yes vs. no PCI, yes vs. no
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary outcomes
All-cause death 0.85 (0.75–0.96) 0.008 0.42 (0.35–0.51) <0.0001
Cardiovascular death or hospitalization 0.87 (0.80–0.95) 0.003 0.62 (0.55–0.70) <0.0001
Secondary outcomes
All-cause death or any hospitalization 0.92 (0.86–0.99) 0.017 0.91 (0.84–0.99) 0.022
Cardiovascular death 0.83 (0.73–0.95) 0.005 0.41 (0.33–0.50) <0.0001
Sudden death from cardiac causes 0.79 (0.64–0.97) 0.027 0.49 (0.36–0.65) <0.0001
Acute myocardial infarction 0.82 (0.61–1.11) 0.20 0.34 (0.20–0.56) <0.0001
Heart failure 0.80 (0.62–1.04) 0.099 0.35 (0.23 – 0.53) <0.0001
Stroke 0.91 (0.54–1.56) 0.73 0.37 (0.16–0.87) 0.023
Any hospitalization 0.95 (0.89– 1.02) 0.18 1.00 (0.92–1.09) 1.00
Cardiovascular hospitalization 0.91 (0.82– 1.02) 0.098 0.73 (0.64–0.84) <0.0001
Acute myocardial infarction 0.96 (0.80–1.16) 0.67 0.81 (0.65–1.02) 0.069
Heart failure 0.86 (0.75–0.98) 0.029 0.67 (0.56–0.80) <0.0001
Stroke 1.18 (0.87–1.62) 0.29 0.40 (0.25–0.64) 0.0002
Ventricular arrhythmia 0.95 (0.65–1.39) 0.79 0.62 (0.37–1.03) 0.066
Acute myocardial infarction or unstable angina 1.01 (0.89–1.14) 0.92 0.96 (0.83–1.11) 0.60
CI, confidence interval; HR, hazard ratio; PCI, percutaneous coronary intervention.
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Table 3 Baseline comparison of placebo- or eplerenone-treated patients in the EPHESUS-PCI group
Characteristic Placebo, n= 781 (49%) Eplerenone, n= 799 (51%) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n Mean±SD or n (%) n Mean±SD or n (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 781 61±12 799 60± 11 0.05
Caucasian 688 (88%) 707 (88%) 0.81
Male gender 591 (76%) 632 (79%) 0.10
Blood pressure (mmHg)
Systolic 781 116±16 799 115± 15 0.43
Diastolic 781 70±11 799 70± 10 0.65
LV ejection fraction (%) 779 33± 6 797 33± 6 0.83
Time from AMI to randomization (days) 781 6.6± 3.0 799 6.8± 3.0 0.23
Previous hospitalization for HF 34 (4%) 26 (3%) 0.25
Symptoms of heart failure 615 (79%) 617 (78%) 0.37
Potassium (mmol/L) 771 4.21± 0.43 795 4.21± 0.43 0.85
Creatinine (μmol/L) 768 94± 25 790 95± 25 0.23
eGFR (MDRD, mL/min/1.73m2) 737 74±19 756 73± 19 0.45
Medical history 781 799
Previous MI 161 (21%) 175 (22%) 0.53
Diabetes mellitus 240 (31%) 244 (31%) 0.93
Heart failure 66 (8%) 56 (7%) 0.28
Hypertension 423 (54%) 425 (53%) 0.70
Medications 781 799
ACEI/ARB 708 (91%) 725 (91%) 0.95
Beta-blockers 648 (83%) 672 (84%) 0.54
Diuretics 406 (52%) 406 (51%) 0.64
Aspirin 739 (95%) 754 (94%) 0.82
Anticoagulant agents 82 (10%) 92 (12%) 0.52
Statins 537 (69%) 532 (67%) 0.36
Symptoms of heart failure: Killip’s class> I.
ACEI, ACE inhibitor, AMI, acute myocardial infarction; eGFR, estimated glomerular filtration rate [four-variable Modification of Diabetes in Renal Disease (MDRD) formula];
HF, heart failure; PCI, percutaneous coronary intervention.
Table 4 Effect of eplerenone on angioplasty-related outcomes in the EPHESUS-PCI cohort
Eplerenone (n= 799) Placebo (n= 781) HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repeat revascularization (PCI/CABG) 51 (6%) 44 (6%) 1.13 (0.75–1.69) 0.56
Angina pectoris 24 (3%) 24 (3%) 0.97 (0.55–1.70) 0.90
Unstable angina 84 (11%) 82 (10%) 1.00 (0.73–1.35) 0.98
Acute myocardial infarction 45 (6%) 52 (7%) 0.83 (0.56–1.24) 0.37
Sudden cardiac death 21 (3%) 30 (4%) 0.67 (0.39–1.17) 0.16
Heart failure 60 (8%) 86 (11%) 0.66 (0.47–0.91) 0.012
Cardiovascular hospitalization 108 (14%) 140 (18%) 0.72 (0.56–0.93) 0.011
CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio.
with numerous other reports.17,18 However, eplerenone adminis-
tration was also an independent factor associated with improved
outcomes, emphasizing the importance of MR antagonism in LVSD
after AMI, including patients treated with primary PCI. Therefore,
prescribing eplerenone to patients with AMI and LVSD remains
beneficial in patients treated with and without PCI.
Whilst the EPHESUS trial included patients with all forms
of AMI [unstable angina, non-ST segment elevation myocardial ..
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. infarcion (NSTEMI), and STEMI] and there was a delay in com-
mencing eplerenone, a recently reported clinical trial (REMINDER:
impact of eplerenone on cardiovascular outcomes in patients post
myocardial infarction, NCT-01176968) has shown that early use
of eplerenone can improve the outcome of patients presenting
with acute STEMI without heart failure.19 Over 1000 patients
were randomized (n= 506/group) to initiation of eplerenone or
placebo within 12–24 h of STEMI. Eplerenone 25 or 50mg/day
(89% patients received 50mg/day) produced a significant reduction
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(HR 0.58, 95% CI 0.45–0.75, P< 0.0001) in the primary endpoint
(a composite of cardiovascular mortality, ventricular arrhythmia,
clinical or subclinical heart failure at 1 month) at a mean follow-up
of 10.5months.19 ALBATROSS (Aldosterone blockade early after
acute myocardial infarction; NCT-01059136) is an ongoing multi-
centre, open-labelled, randomized trial to assess the effects of MR
blockade with a 200mg i.v. bolus of potassium canrenoate followed
by 25mg/day spironolactone for 6 months in 1600 patients with
STEMI or high risk NSTEMI.20
Eplerenone did not affect PCI-related
outcomes
Mineralocorticoid receptors are widely distributed in the vas-
cular system, including endothelial cells, endothelial progenitor
cells (EPCs), vascular smooth muscle cells (VSMCs), and intact
vessels.8,21,22 These receptors also influence vascular function and
remodelling;6,23 MR activation has been shown to increase prolifer-
ation of VSMCs6 and to impair differentiation and proliferation of
EPCs.7 These characteristics suggest that MR activation is a poten-
tial stimulus for neointimal proliferation and restenosis. In humans,
elevated baseline plasma aldosterone levels directly correlate with
risk of restenosis24 and inversely correlate with circulating EPCs
and endothelial colony-forming units.8 Mineralocorticoid receptor
antagonists reduce atherosclerosis,23,25 prevent adverse vascular
remodelling,26 and attenuate post-angioplasty neointimal prolifer-
ation in experimental animals.9,11,27
Spironolactone has been shown to inhibit neointimal prolif-
eration after balloon angioplasty of iliac arteries in rabbits.27
However, these results could not be reproduced in a porcine coro-
nary angioplasty model,9,28 which is the gold standard pre-clinical
model for restenosis. Additionally, a single-centre clinical trial failed
to show any effect of spironolactone in reducing restenosis.29
Nevertheless, promising experimental data have been obtained
with eplerenone.9–11 Our data suggest that, like spironolactone,
eplerenone does not appear to affect PCI-related clinical out-
comes. Therefore, eplerenone cannot currently be recommended
for patients undergoing PCI without co-existing AMI or LVSD.
Study limitations
This study has several limitations. It is a post-hoc analysis with
inherent shortcomings of any such study. Patients in the EPHESUS
PCI cohort did not have routine angiographic follow-up to docu-
ment any effect of eplerenone on angiographic restenosis; however,
our assessment of clinical events is perhaps more relevant than
angiographic outcomes.
Conclusion
The beneficial effects of eplerenone on heart failure events and
hospitalization seen in the EPHESUS trial are similar for both
PCI-treated and non-PCI-treated AMI patients with LVSD. There
is no evidence that eplerenone reduces the risk of recurrent
ischaemia-related events including recurrence of angina or the ..
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.. need for repeat revascularization. Use of eplerenone is strongly
recommended in AMI patients with LVSD.
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